These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22828124)

  • 1. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.
    Frederich R; McNeill R; Berglind N; Fleming D; Chen R
    Diabetol Metab Syndr; 2012 Jul; 4(1):36. PubMed ID: 22828124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.
    White JL; Buchanan P; Li J; Frederich R
    BMC Endocr Disord; 2014 Feb; 14():17. PubMed ID: 24565221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
    Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment.
    Perl S; Cook W; Wei C; Iqbal N; Hirshberg B
    Diabetes Ther; 2016 Sep; 7(3):527-35. PubMed ID: 27402391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
    Konya H; Yano Y; Matsutani S; Tsunoda T; Ikawa T; Kusunoki Y; Matsuo T; Miuchi M; Katsuno T; Hamaguchi T; Miyagawa J; Namba M
    Ther Clin Risk Manag; 2014; 10():547-58. PubMed ID: 25050065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies.
    Davidson JA
    J Manag Care Pharm; 2014 Feb; 20(2):120-9. PubMed ID: 24456313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Liu H; Hu Y; Li FF; Liu BL; Su XF; Ma JH
    Diabetes Ther; 2016 Dec; 7(4):743-753. PubMed ID: 27734321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy.
    Bryzinski B; Allen E; Cook W; Hirshberg B
    J Diabetes Complications; 2014; 28(6):887-93. PubMed ID: 25168266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
    Gantz I; Okamoto T; Ito Y; Sato A; Okuyama K; O'Neill EA; Engel SS; Lai E;
    Diabetes Ther; 2017 Aug; 8(4):793-810. PubMed ID: 28589493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Perl S; Cook W; Wei C; Ohman P; Hirshberg B
    Clin Ther; 2016 Dec; 38(12):2578-2588. PubMed ID: 27823868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
    Mintz ML; Minervini G
    Curr Med Res Opin; 2014 May; 30(5):761-70. PubMed ID: 24397584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
    DeFronzo RA; Hissa MN; Garber AJ; Luiz Gross J; Yuyan Duan R; Ravichandran S; Chen RS;
    Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.